Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (331)	8/4/1999 10:52:00 PM
From: Steve	Read Replies (1) \| Respond to of 496

Maybe whatever Guilford and Amgen do should be kept to themselves. Boy, did the stock take a plunge today. I listened to the conference call. Guilford has so many things in the pipeline: NIL-A, Naaladase, Parp, high concentration Gliadel, expansion of Gliadel use, Paclimer, and even dopascan is finally seeing some activity. It is hard to believe that a biotech company this small has all of these things going on at once. I don't understand why they punished the stock after the conference call. It all sounded good to me. Any thoughts by anyone?